SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| Eranza | 1000 mg | Powder for concentrate for solution for infusion · Intravenous use | 10 Vial | SAR 1191.85 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| INVANZ 1 gm Powder for Concentrate for Solution for Infusion | 1 g | Powder for concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 133.65 | NCE · Prescription | MERCK SHARP & DOHME LIMITED | Valid |
Indications — CHI Daman Drug Formulary
Pyogenic Arthritis
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| INVANZ | EQ 1GM BASE/VIAL | injectable · intramuscular, intravenous | MSD SUB MERCK | Prescription | 21 Nov 2001 |
| ERTAPENEM SODIUM | EQ 1GM BASE/VIAL | injectable · intramuscular, intravenous | ACS DOBFAR SPA | Prescription | 16 Apr 2018 |
| ERTAPENEM SODIUM | EQ 1GM BASE/VIAL | injectable · intramuscular, intravenous | EUGIA PHARMA | Prescription | 25 Jun 2018 |
| ERTAPENEM SODIUM | EQ 1GM BASE/VIAL | injectable · intramuscular, intravenous | SAVIOR LIFETEC CORP | Prescription | 19 Mar 2019 |
| ERTAPENEM SODIUM | EQ 1GM BASE/VIAL | injectable · intramuscular, intravenous | GLAND | Prescription | 26 Mar 2021 |
| ERTAPENEM SODIUM | EQ 1GM BASE/VIAL | injectable · intramuscular, intravenous | QILU ANTIBIOTICS | Prescription | 31 Oct 2024 |
| ERTAPENEM SODIUM | EQ 1GM BASE/VIAL | injectable · intramuscular, intravenous | SUN PHARM | Discontinued | 2 May 2023 |
EMA European Union — centrally authorised medicines
Invanz Merck Sharp & Dohme B.V. · Authorised · authorised 18 Apr 2002 · ATC J01DH03
Therapeutic indication (EMA)
Treatment Treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required: intra-abdominal infections; community-acquired pneumonia; acute gynaecological infections; diabetic foot infections of the skin and soft tissue. Prevention Invanz is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Ertapenem SUN SUN Pharmaceutical Industries (Europe) B.V. · Authorised · authorised 15 Jul 2022
Therapeutic indication (EMA)
Treatment Ertapenem SUN is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4.4 and 5.1): Intra-abdominal infections Community acquired pneumonia Acute gynaecological infections Diabetic foot infections of the skin and soft tissue (see section 4.4) Prevention Ertapenem SUN is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Ertapenem Hospira Hospira UK Limited · Application withdrawn · ATC J01DH03
Therapeutic indication (EMA)
Treatment of bacterial infections and prophylaxis of surgical site infection following elective colorectal surgery.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| ERTAPENEM FOR INJECTION | 02490773 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | JUNO PHARMA CANADA INC. |
| ERTAPENEM FOR INJECTION | 02492148 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | AURO PHARMA INC |
| ERTAPENEM FOR INJECTION | 02496127 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | FRESENIUS KABI CANADA LTD |
| ERTAPENEM FOR INJECTION | 02511150 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | DR REDDY'S LABORATORIES LTD |
| ERTAPENEM FOR INJECTION | 02537176 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | EUGIA PHARMA INC. |
| INVANZ | 02247437 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | MERCK CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | ERTAPENEM 1 GRAM VIAL | $26.62948 | per EA | 23 Sep 2026 |
| US NADAC | ERTAPENEM 1 GRAM VIAL | $47.2056 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Ertapenem 1g powder for solution for infusion vials | £31.65 | 1 vial | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.